Market News & Trends
Edge Therapeutics Announces Commercial Supply Agreement With Oakwood Laboratories
Edge Therapeutics, Inc. recently announced it has entered into a supply agreement and an amended and restated development agreement with Oakwood Laboratories for the…
M Pharmaceutical In-Licenses Novel Pediatric Orphan Drug
M Pharmaceutical Inc. recently announced that it has in-licensed a novel drug product that should qualify as an Orphan Drug under the US Orphan Drug…
Inovio’s DNA-Based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation
Inovio Pharmaceuticals, Inc. recently announced its DNA-based monoclonal antibody product for flu produced broadly cross-reactive antibodies that provided complete protection from a lethal challenge with…
Financial Milestone Achieved in Catalyst’s Subcutaneous Factor IX Program
Catalyst Biosciences, Inc. recently announced it has achieved a financial milestone under its collaboration with ISU Abxis. In June 2017, the first patient and cohort…
Heart Failure Market to Surpass $16 billion by 2026
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK, and Japan is set to grow from…
Prothena Announces Initiation of Phase 2 Study, Triggers Milestone
Prothena Corporation plc recently announced that the first patient has been enrolled in PASADENA, a global Phase 2 study of PRX002/RG7935 in patients with early…
Onxeo Announces Positive Preclinical Results
Onxeo S.A. recently announced positive preclinical proof-of-concept results confirming the activity via systemic (intravenous, IV) administration of AsiDNA, the company’s first-in-class DNA repair inhibitor. A…
Galapagos NV Announces New Phase 2 Study
“We are pleased with the initiation of this new Phase 2 study with filgotinib," said Dr. Walid Abi-Saab, Chief Medical Officer of Galapagos. "We look…
Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial
Cytokinetics, Inc. recently announced that data relating to patient baseline characteristics and the reasons for patient screen failure, both from the first cohort of the…
ProQR’s Drug Candidate Receives Orphan Drug Designation
ProQR Therapeutics N.V. recently announced its investigational drug QRX-411 has received orphan drug designation (ODD) from the US FDA and EMA for the treatment of…
Horizon Discovery Takes Exclusive License for Novel Transposon-Based Gene-Editing Technology Platform
Horizon Discovery Group plc recently announced the completion of licensing agreements with all joint patent holders to provide exclusive worldwide rights to a novel transposon-based…
BeiGene Initiates Pivotal Trial of PD-1 Antibody
BeiGene, Ltd. recently announced that the first patient was dosed in a pivotal clinical trial in China of BGB-A317, an investigational anti-PD-1 antibody, in patients…
Auris Medical Completes Enrollment of Phase 3 Trial
Auris Medical Holding AG recently announced it has completed patient enrollment in the Phase 3 HEALOS clinical trial of AM-111 in idiopathic sudden sensorineural hearing…
Lonza Completes Acquisition of Capsugel, Creating Leading Integrated Solutions Provider
Lonza announced that following the receipt of all required regulatory approvals, it has completed the acquisition of Capsugel S.A. from KKR for $5.5 billion in…
Enable Injections Introduces First Multi-Vial/Multi-Syringe Biologics Delivery System
Enable Injections, Inc., the developer of advanced large-volume wearable injectors (LVWI) for subcutaneous delivery of biologics and high-volume drugs, recently announced a new single-,…
Microneedles - A Novel Alternative in Selected Drug Delivery Areas
Microneedles are a novel drug delivery technology that can offer promising advantages as an alternative to classical needle injections and other routes of…
CordenPharma & GE Healthcare Offer Unique End-to-End Solution to Accelerate Oligonucleotide Drug Development
CordenPharma International and GE Healthcare’s Dharmacon business have entered a strategic collaboration to create an end-to-end solution for oligonucleotide-based drug discovery. The collaboration will address…
Argenx Receives Second Preclinical Milestone Payment in Collaboration With LEO Pharma
Argenx recently announced the achievement of the second of two preclinical milestones in connection with its collaboration with LEO Pharma. "Our collaboration with LEO Pharma…
Neos Therapeutics Announces FDA Approval of Extended-Release Orally Disintegrating Tablets
Neos Therapeutics, Inc. recently announced that the US FDA approved Cotempla XR-ODT, the first and only methylphenidate extended-release orally disintegrating tablet for the treatment of…
ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis
ARCA biopharma, Inc. recently announced database lock for the GENETIC-AF Phase 2B interim efficacy analysis, to be conducted by the trial Data Safety Monitoring Board…
